2-(2-Methoxy-4-nitrophenyl)acetaldehyde → 1-[2-(2,1,3-Benzoxadiazol-5-yl)ethyl]-4-[2-(2-methoxy-4-nitrophenyl)ethyl]piperazin-2-one
Reaktionsgleichung
[N:1]1[O:2][N:3]=[C:4]2[CH:9]=[C:8]([CH2:10][CH2:11][N:12]3[CH2:17][CH2:16][NH:15][CH2:14][C:13]3=[O:18])[CH:7]=[CH:6][C:5]=12.[CH3:19][O:20][C:21]1[CH:26]=[C:25]([N+:27]([O-:29])=[O:28])[CH:24]=[CH:23][C:22]=1[CH2:30][CH:31]=O>>[N:1]1[O:2][N:3]=[C:4]2[CH:9]=[C:8]([CH2:10][CH2:11][N:12]3[CH2:17][CH2:16][N:15]([CH2:31][CH2:30][C:22]4[CH:23]=[CH:24][C:25]([N+:27]([O-:29])=[O:28])=[CH:26][C:21]=4[O:20][CH3:19])[CH2:14][C:13]3=[O:18])[CH:7]=[CH:6][C:5]=12Komponenten
3
Versuchsvorschrift
The title compound was prepared from 1-[2-(2,1,3-Benzoxadiazol-5-yl)ethyl]piperazin-2-one and (2-Methoxy-4-nitrophenyl)acetaldehyde following essentially the same procedure as Example 6. The product was purified by mass-directed reverse phase HPLC (AcCN-Water with 0.1% TFA). LC-MS (IE, m/z): 426 [M+1]+.
Aufarbeitung
- customThe product was purified by mass-directed reverse phase HPLC (AcCN-Water with 0.1% TFA)